Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) will report third fiscal quarter 2026 financial results for the period ended December 31, 2025 on Friday, February 13, 2026. Management will host a conference call and webcast at 8:00 AM Eastern Time the same day. Investors can join by dialing the domestic number 1-877-407-0784 or the international number 1-201-689-8560 using Conference ID 13758405. A live webcast will be available via the company’s Events page, and an online replay will be posted about one hour after the call.
Positive
- None.
Negative
- None.
News Market Reaction – XAIR
In the Jan 27 session, XAIR declined 7.53%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.2% during that session. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 23 | Earnings call scheduling | Neutral | +4.0% | Announced Q2 FY2026 results release and 4:30 PM ET conference call details. |
| Jul 25 | Earnings call scheduling | Neutral | -3.6% | Set date and time for Q1 FY2026 financial results call and webcast. |
| May 20 | Earnings call scheduling | Neutral | +1.5% | Announced fiscal Q4 and full-year 2025 results release and investor call. |
| Jan 27 | Earnings call scheduling | Neutral | -1.8% | Scheduled fiscal Q3 2025 results release and 4:30 PM ET conference call. |
| Oct 29 | Earnings call scheduling | Neutral | +8.8% | Set timing for fiscal Q2 2025 earnings release and related investor webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings calls has historically produced modest, mixed single-day moves around these announcements, with an average move of about 3.93% and no clear directional bias.
Over the past year, Beyond Air has regularly announced financial results conference calls, including fiscal Q2 and Q1 2026, fiscal year-end 2025, and prior quarterly results. These releases, all tagged “conferences,earnings”, typically paired standard dial-in details with timing for quarterly or annual reports. Single-day reactions to these scheduling notices have ranged from modest declines to gains, averaging 3.93%, suggesting traders have treated them as routine updates rather than major catalysts.
Key Terms
nitric oxide medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time the same day.
| Conference Call & Webcast | |
| Friday, February 13th@ 8:00 AM ET | |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13758405 |
| Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call. |
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
CONTACTS:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
